Paper Details

  1. Home
  2. Paper Details

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.

Author: CadiouM, HayatM, MandelliF, PeetermansM, PettiM C, SolbuG, StryckmansP, SuciuS, ThalerJ, WillemzeR, ZittounR, de WitteT

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

GM-CSF administered during induction treatment of AML with a DNR/Ara-C combination did not provide any clinical benefit. Furthermore, there was a significant decrease in the CR rate with more persistent leukemia when GM-CSF was administered during the hypoplastic phase after the chemotherapy courses.
Paper Details　
Original Abstract of the Article :
PURPOSE: To assess the value of granulocyte-macrophage colony-stimulating factor (GM-CSF) for induction treatment of acute myeloid leukemia (AML), both for priming of leukemic cells and for acceleration of hematopoietic recovery. PATIENTS AND METHODS: GM-CSF was administered 5 micrograms/kg/d by co...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1996.14.7.2150

データ提供：米国国立医学図書館（NLM）

Evaluating the Role of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Acute Myelogenous Leukemia (AML) Treatment

Acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow. This study investigated the potential benefits of using granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein that helps stimulate the production of white blood cells, in the treatment of AML.

GM-CSF's Impact on AML Treatment

The researchers conducted a randomized trial to assess the effects of GM-CSF on AML patients during induction therapy. Surprisingly, they found that administering GM-CSF did not improve the overall outcome of treatment. In fact, patients receiving GM-CSF during the hypoplastic phase (when the bone marrow is suppressed) after chemotherapy had a lower complete remission rate and a higher risk of persistent leukemia.

Understanding the Limitations of Treatment Options

This study highlights the importance of careful consideration when evaluating new treatment options for complex diseases like AML. While GM-CSF has shown promise in other contexts, this research demonstrates that its application in AML treatment may not be beneficial and may even have negative consequences. This underscores the need for ongoing research to identify effective and safe therapies for AML patients.

Dr.Camel's Conclusion

Just like a camel needs to navigate the desert's shifting sands, researchers are constantly exploring new approaches to fight diseases like AML. This study serves as a reminder that while new technologies and treatments hold great promise, their effectiveness must be carefully evaluated before widespread adoption. By learning from research findings, we can continue to refine our understanding of these complex diseases and develop treatments that truly benefit patients.

Date :
  1. Date Completed 1996-08-22
  2. Date Revised 2017-02-10
Further Info :

Pubmed ID

8683249

DOI: Digital Object Identifier

10.1200/JCO.1996.14.7.2150

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.